ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 117,50
0,31%
Dow Jones
39 671,04
-0,51%
DAX
18 732,54
0,27%
Brent Oil
81,585
0,07%
Bitcoin
69 688,51
0,85%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMS)

  7. NewAmsterdam Pharma Company NV (NAMS) Actualités

NAMS

NewAmsterdam Pharma Comp... (NAMS)

NewAmsterdam Pharma Company NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NAMS
DateHeureSourceTitreSymboleSociété
21/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSNewAmsterdam Pharma Company NV
09/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSNewAmsterdam Pharma Company NV
03/05/202422h01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSNewAmsterdam Pharma Company NV
02/05/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024NASDAQ:NAMSNewAmsterdam Pharma Company NV
09/04/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
01/04/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
25/03/202413h00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology CongressNASDAQ:NAMSNewAmsterdam Pharma Company NV
12/03/202413h00GlobeNewswire Inc.NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVDNASDAQ:NAMSNewAmsterdam Pharma Company NV
28/02/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:NAMSNewAmsterdam Pharma Company NV
26/02/202414h00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in MarchNASDAQ:NAMSNewAmsterdam Pharma Company NV
14/02/202404h40GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
13/02/202422h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSNewAmsterdam Pharma Company NV
01/02/202422h01GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
08/01/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of DirectorsNASDAQ:NAMSNewAmsterdam Pharma Company NV
04/01/202414h00GlobeNewswire Inc.NewAmsterdam Pharma Announces 2024 Strategic PrioritiesNASDAQ:NAMSNewAmsterdam Pharma Company NV
13/11/202314h00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
23/10/202314h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
21/09/202313h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 MutationNASDAQ:NAMSNewAmsterdam Pharma Company NV
20/09/202314h00GlobeNewswire Inc.NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
14/08/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial OfficerNASDAQ:NAMSNewAmsterdam Pharma Company NV
07/08/202313h15GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
25/07/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular DiseaseNASDAQ:NAMSNewAmsterdam Pharma Company NV
09/06/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
07/06/202305h25GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
06/06/202322h01GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary SharesNASDAQ:NAMSNewAmsterdam Pharma Company NV
05/06/202313h00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese PatientsNASDAQ:NAMSNewAmsterdam Pharma Company NV
03/06/202318h15GlobeNewswire Inc.NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
31/05/202314h00GlobeNewswire Inc.NewAmsterdam Pharma to Present at Jefferies Healthcare ConferenceNASDAQ:NAMSNewAmsterdam Pharma Company NV
23/05/202314h00GlobeNewswire Inc.NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023NASDAQ:NAMSNewAmsterdam Pharma Company NV
08/05/202314h00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial HighlightsNASDAQ:NAMSNewAmsterdam Pharma Company NV
 Showing the most relevant articles for your search:NASDAQ:NAMS

Dernières Valeurs Consultées

USOTC
BSFAF
BSF Enterprise (QB)
EU
AAG2L
Credit Agricole Sa null
BOV
SOJA3R
Boa Safra Sementes ON
LSE
96QQ
Municplty.40
USOTC
SSDEF
SSGA SPDR ETFS Europe I (GM)
SUSHI
SUSDETH
Synth sUSD
ASX
FXLKOD
EU
BFCGN
Banque Federative Senior...
BOV
SLBG34R
SLB
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés